These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 19860621

  • 1. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
    Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, Grapulin L, Sacco M, Torelli F, Vignetti M, Mandelli F, Foà R, Pulsoni A.
    Leuk Lymphoma; 2009 Nov; 50(11):1803-8. PubMed ID: 19860621
    [Abstract] [Full Text] [Related]

  • 2. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
    Tarasenkova AA, Filatova LV, Gershanovich ML, Semiglazova TIu.
    Vopr Onkol; 2012 Nov; 58(1):101-9. PubMed ID: 22629838
    [Abstract] [Full Text] [Related]

  • 3. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P.
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [Abstract] [Full Text] [Related]

  • 4. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
    Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A.
    J Clin Oncol; 2011 Nov 10; 29(32):4234-42. PubMed ID: 21990399
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma?
    Eichenauer DA, Engert A.
    Leuk Lymphoma; 2009 Nov 10; 50(11):1733-4. PubMed ID: 19883301
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
    Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V.
    Ann Oncol; 2000 Sep 01; 11(9):1105-14. PubMed ID: 11061603
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.
    Diehl V, Sieber M, Rüffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H.
    Ann Oncol; 1997 Feb 01; 8(2):143-8. PubMed ID: 9093722
    [Abstract] [Full Text] [Related]

  • 18. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
    Shankar A, Hayward J, Kirkwood A, McCarthy K, Hewitt M, Morland B, Daw S.
    Br J Haematol; 2014 May 01; 165(4):534-44. PubMed ID: 24754633
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
    Kedmi M, Apel A, Davidson T, Levi I, Dann EJ, Polliack A, Ben-Bassat I, Nagler A, Avigdor A.
    Acta Haematol; 2016 May 01; 135(3):156-61. PubMed ID: 26588173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.